MK4280A-700
09 Dec 2020
Trial Summary
A phase 3 study of MK-4280 plus MK-3475 (pembrolizumab) vs. regorafeneb in 3L+ mCRC
Acronym:
MK4280A-700
ACTRN/NCT /ethics:
n/a
Scientific title:
A phase 3 study of MK-4280 plus MK-3475 (pembrolizumab) vs. regorafeneb in 3L+ mCRC
Sponsor / Cooperative group:
n/a
Trial & Patient Characteristics
| Cancer Type | Bowel and colon |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | All stages |
| Anticipated Start Date | - |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Pamela Cooper |
| pamela.cooper@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Professor Tim Price |
| Recruitment Status | Not Yet Recruiting |